What’s the key information?
- Event format: Panel discussion with audience Q&A followed by a networking lunch
- Event date: Thursday 25 February 2026
- Event time: 12:00 pm – 1:15 pm (Networking lunch: 1:15 pm – 2:00 pm)
- Event location: LT300, City & Guilds Building, Imperial College London
Who should attend?
Academics and early-career researchers from Imperial College London with an interest in commercialising their research through spinouts or licensing.
Please note: Attendance at this event is reserved for Imperial College London staff.
What will we cover?
How do you make IP work for you when commercialising your research? Let our panel of leading patent attorneys, industry experts and academics at different stages of the commercialisation journey guide you by sharing their insights and experiences.
We’ll be covering the following topics:
- Defining the commercial endpoint before you file a patent application
- How to file patents at the right moment to align with your plans for publication and commercialisation
- How to prioritise what is protectable and valuable
- Using the patent timeline as a strategic roadmap and planning tool
- Ensuring your IP is investment-ready
- What makes a good licensable technology?
Who’s on the panel?
The session will be hosted by leading patent attorneys from Venner Shipley, a leading European full service IP firm.
Professor Eric Aboagye, FMedSci
Eric is Professor of Cancer Pharmacology & Molecular Imaging at Imperial and Director of the CRUK-EPSRC-MRC-NIHR Comprehensive Cancer Imaging Centre. He is an experienced academic entrepreneur with numerous licences in the field of medical imaging, as well as a recent spinout founder with NuclearMedix, which is developing scalable and accessible radiopharmaceuticals for enhanced patient care.
Professor Paul Mitcheson
Paul is Professor of Electrical Energy Conversion in the Control and Power Research Group in the Department of Electrical and Electronic Engineering at Imperial. He is the founder of two spinout companies focusing on advanced wireless power transfer, and is currently Chief Scientific Officer of Bumblebee Power, which is commercialising position-tolerant wireless charging solutions for electric scooters, autonomous systems and portable devices.
Mel Glossop
A Program Director at Apollo Therepeutics, Mel is an experienced pharma and biotech executive having held senior roles at Centauri Therapeutics and Pfizer. Mel is a fellow of the Royal Society of Chemistry and a Chartered Chemist.
What else do I need to know?
- Please complete your registration in full to confirm your job title, company, and dietary and accessibility requirements.
- This is a ticketed event with limited space.
- Venue accessibility information can be viewed via AccessAble.
- Any questions, please contact Gavin Reed g.reed@imperial.ac.uk
- All guests registering for this event will be expected to adhere to Imperial’s Conference Policy
- Imperial College London – Enterprise Division Privacy Notice